Cannabix (BLOZF) Adds Nationally Renowned Expert Dr. Marilyn Huestis to Advisory Board
ACCESS Newswire
SEATTLE, WA / ACCESSWIRE / April 21, 2016 / Cannabix Technologies Inc. (BLOZF)(CSE:BLO), developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, recently announced the appointment of Dr. Marilyn Huestis to its Scientific Advisory Board. As a leading expert on human drug testing, and more specifically, the effects of marijuana use on driving, she advises many different organizations, including the Transportation Research Board Committee on Alcohol and Other Drugs and the National Safety Council's Alcohol, Drugs, and Impairment Division.
Dr. Huestis, who on February 5th retired from her 23 year career as the Senior Investigator and Chief of Chemistry and Drug Metabolism at the National Institute on Drug Abuse, will assist the company in developing the Cannabix Marijuana Breathalyzer as a tool for law enforcement to determine if a driver is impaired. The durable, portable hand-held tool leverages FAIMS-MS technology to quickly and accurately measure THC levels in breath.
State Laws Remain Inconsistent
There are many different state laws addressing driver impairment, but these rules vary greatly between states, even from a medical point of view. Of the four states where recreational marijuana has been legalized, two have no laws on the books at all to address marijuana impairment, while Colorado and Washington only permit 5ng/mL of THC per se. Some medical marijuana states, like Nevada, have implemented similar rules or zero-tolerance rules, while some states that have no marijuana programs even have set tolerance levels.
The idea of having limits for THC seems logical. After all, everyone knows that a 0.08 blood alcohol levels is a limit for drinking and driving. The problem is that THC levels cannot be measured in the same way, which means many law enforcement agencies rely on intrusive blood testing combined with roadside tests to enforce the rules. When push comes to shove, these are difficult measures to enforce on the streets compared to breathalyzer testing.
In the below interview Dr. Huestis goes in detail about the testing done to determine comparable impairment levels:
Defining What Constitutes Impairment
Dr. Huestis and her team were seeking to discover the comparable intoxication levels of someone who had a .08 BAL with the ng level of THC in their system through a series of tests. These tests were conducted in a driving simulator after calibrating each individual drivers eyes and reaction times. After completing the tests, Dr. Huestis was able to create a model where they showed the concentration of THC that was equivalent to a .08 BAL was 13.1ng/mL.
States that allow 5ng/mL of THC per se are on the right track with having a measurable number, but they are wildly off as to what the number is appropriate. If 13.1ng/mL is equivalent to a .08 BAL, then the allowable limit in Colorado and Washington of 5ng/mL is the same as a .03 BAL, which might be too restrictive for many cannabis users.
The bigger problem is the lack of a hand held marijuana Breathalyzer that can reliably test drivers for on the spot.
"THC concentrations typically peak during the act of smoking, while peak 11-OH THC concentrations occur approximately 9-23 minutes after the start of smoking. Concentrations of both analytes decline rapidly and are often < 5 ng/mL at 3 hours. Significant THC concentrations (7 to 18 ng/mL) are noted following even a single puff or hit of a marijuana cigarette."
If a law enforcement officer (LEO) has to wait a couple of hours before drawing blood for a test, it is likely that the THC levels at that point would have decreased below the 5 ng/mL threshold.
Cannabix Technologies Solution
There is a clear need for both consistent state laws and a reliable hand held Breathalyzer that law enforcement officers can use on the spot. While Cannabix is already well on the path to accomplishing the latter, the addition of Dr. Huestis should not only expedite the process and lend a further air of credibility to the work that they are already doing. Dr. Huestis will work with the company in the development of its marijuana breathalyzer and provide key guidance on testing and regulatory approvals moving forward.
Cannabix Technologies was founded by a former member of the Royal Canadian Mounted Police (Kal Malhi), who noticed that the standard practice of administering a sobriety test, followed by an invasive blood test or inaccurate mouth swab was simply not effective enough of a tool against impaired drivers.
His co-founder is a biomedical engineer and medical doctor by the name of Rav Mlait, who became alarmed by the number of large wrecks come through his hospital, many of which were the result of impaired driving.
Investors interested in the cannabis industry may want to check out the company as it works to launch its beta prototype and test it with law enforcement agencies around the world. In many ways, the company offers an interesting alternative to some of the other cannabis plays in the space such as General Cannabis Corp. (CANN), OrganiGram Holdings Inc. (OGRMF), or Medical Marijuana Inc. (MJNA) in that it addresses a law enforcement opportunity.
CFN Media (CannabisFN), the leading creative agency and media network dedicated to legal cannabis, helps marijuana companies attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across the US and Canada. Today, CFN Media is also the emerging digital media choice for the top brands in the space.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Important factors that could cause these differences include, but are not limited to, the demand for the company's services, governmental regulation of the cannabis industry, and the company's ability to execute its business plan. Emerging Growth LLC dba TDM Financial, which owns CFN Media, is not registered with any financial or securities regulatory authority, and does not provide nor claim to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CFN Media, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.
